Psychiatry · free tool
Guideline Finder
The RANZCP position statements, practice guidelines and national guidelines your MEQ and CEQ answers should name: what each recommends, a sentence you can write to cite it, what changed recently and the outdated answer to avoid. Quiz yourself, flip flashcards, print a cheat sheet. Free, no sign-up.
40 guidelines · 13 from RANZCP · 12 recently changed · checked 2026-11
You know 0%
RANZCP exam guideline cheat sheet · checked 2026-11 · fellowshipready.com.au
Major depression in adults: first-line treatment by severity: Depression in adults: treatment and management (NICE guideline NG222) (NICE (UK), NG222 (June 2022)). Severity is split into 'less severe' (PHQ-9 under 16) and 'more severe' (16 or more). Less severe: start with the least intrusive option, such as guided self-help, CBT, behavioural activation or exercise. Do not routinely offer an antidepressant first unless the person prefers one. More severe: combined individual CBT and an antidepressant is the preferred option. Continue an antidepressant for at least 6 months after remission, and taper rather than stop abruptly. Paroxetine and venlafaxine need particular care.
Bipolar disorder: long-term treatment and valproate: Bipolar disorder: assessment and management (NICE clinical guideline CG185) (NICE (UK), CG185 (2014, updated; last reviewed July 2024)). Lithium is the first-line long-term treatment for bipolar disorder. Do not offer valproate to women or girls who could become pregnant. The guideline follows MHRA valproate safety advice. MHRA advice from September 2024 adds that men taking valproate should use effective contraception, with their partners, during treatment and for 3 months after stopping. For acute mania, stop any antidepressant and offer an antipsychotic. Antidepressant monotherapy is avoided in bipolar disorder.
ECT: indications and the College position: Electroconvulsive therapy (ECT) position statement, with the RANZCP ECT Professional Practice Guideline (RANZCP, PS #74 (October 2019); ECT PPG (Weiss et al., ANZJP 2019)). ECT is an evidence-based treatment for severe depression, mania and psychosis, with the strongest evidence in severe depression. Access should not be restricted by cost, service availability, age, medical comorbidity or overly restrictive legislation when ECT is clinically indicated. Psychiatrists who prescribe or give ECT need appropriate training and ongoing education. Psychiatrists should work to reduce stigma about ECT and improve access.
Ketamine and esketamine for treatment-resistant depression: Professional practice guidelines for the use of ketamine in psychiatric practice (PPG 24) (RANZCP, PPG 24 (Board-approved October 2024; published May 2025)). In clinical practice, ketamine therapy is limited to treatment-resistant depression. Other uses belong in research or formal access programs. Intranasal esketamine is TGA-approved for TRD with a new antidepressant. Racemic ketamine for depression is off-label. A credentialed psychiatrist (or a practitioner they supervise) assesses and prescribes, with informed consent and a follow-up plan in place before starting. Monitor for 2 hours after each dose (BP, dissociation), screen for bladder, liver, cognitive and misuse problems, and audit practice at least annually.
MDMA for PTSD and psilocybin for treatment-resistant depression: Clinical memorandum: Therapeutic use of MDMA for PTSD and psilocybin for treatment resistant depression (RANZCP, Version 1.0 (May–June 2023)). From 1 July 2023, only psychiatrists can prescribe MDMA (for PTSD) or psilocybin (for TRD). They need TGA Authorised Prescriber approval and HREC approval of a protocol. The evidence is limited and of low certainty, so use is restricted to people for whom established treatments have not worked. Psychotherapy is a core part of treatment, delivered within a multidisciplinary governance framework with clear escalation pathways. People with a personal or family history of psychosis were generally excluded from trials. Record outcomes and adverse events systematically.
First-episode psychosis: early intervention: Australian Clinical Guidelines for Early Psychosis (Orygen, 2nd edition (updated)). Duration of untreated psychosis is a risk factor for poor outcome that can be changed. Early detection and timely, comprehensive treatment are central. Early intervention can reduce distress, may improve short-term outcomes, and is considered cost-effective. Intervening in the at-risk (putative prodromal) phase may help prevent the onset of psychosis. Care for young people should be comprehensive and youth-focused, including psychosocial and family support as well as medication.
Treatment-resistant schizophrenia: when to offer clozapine: Psychosis and schizophrenia in adults: prevention and management (NICE clinical guideline CG178) (NICE (UK), CG178 (2014)). Treatment resistance means inadequate response despite adequate doses of at least two different antipsychotics, one of them a non-clozapine second-generation antipsychotic. Offer clozapine after two adequate antipsychotic trials have failed. Combine medication with psychological and family interventions and physical health monitoring.
Metabolic monitoring on antipsychotics: Positive Cardiometabolic Health Resource: an early intervention framework for people on psychotropic medications (NSW/Australian adaptation) (HETI / NSW (adapted from Curtis, Newall and Samaras), 2023 update). The core message is not just to screen but to intervene when a person is in the 'red zone'. Check weight, waist, BP, glucose and lipids at baseline, at 3, 6, 9 and 12 months, then every 6 months. Weigh weekly to fortnightly for the first 6–8 weeks. Review promptly if weight rises by 5 kg or more within 3 months. Consider metformin for impaired glucose or rapid weight gain, and choose lower-risk antipsychotics. Red-zone triggers include smoking, BMI over 25, waist over 94 cm (men) or 80 cm (women), BP over 140/90, HbA1c 6.0% or higher, and abnormal lipids.
PTSD: first-line treatment: Australian Guidelines for the Prevention and Treatment of Acute Stress Disorder, Posttraumatic Stress Disorder and Complex PTSD (Phoenix Australia, 3rd edition (2020)). For adults with PTSD, specific trauma-focused psychological therapies (trauma-focused CBT) are strongly recommended as first line. Several other psychological interventions get conditional recommendations. When medication is indicated, use sertraline, paroxetine, fluoxetine or (new in this edition) venlafaxine. For children and adolescents, trauma-focused CBT, alone or with a caregiver, is strongly recommended.
Antipsychotics for behavioural and psychological symptoms of dementia: Antipsychotic medications as a treatment of behavioural and psychological symptoms of dementia (RANZCP, RANZCP position statement (current online version)). Treat BPSD mainly with non-drug strategies, guided by a person-centred, culturally appropriate multidisciplinary assessment. Use antipsychotics only for severe or disabling psychosis, aggression or agitation, or where there is a risk of significant harm, after weighing risks and benefits. Use one drug at a time, start low and go slow, and stop promptly if significant adverse effects occur. Time-limit prescriptions and trial tapering every 3–6 months. Get informed consent from the patient or substitute decision-maker.
Psychotropics for behaviours of concern in cognitive disability or dementia: Psychotropic Medicines in Cognitive Disability or Impairment Clinical Care Standard (Australian Commission on Safety and Quality in Health Care, 2024). Eight quality statements and seven indicators cover the safe use of psychotropics in people with intellectual disability, autism, dementia or other cognitive impairment. Assess for causes of the behaviour and use non-drug, person-centred supports first. Psychotropics to manage behaviour are a last resort. Get informed consent, document the purpose, and review regularly with a plan to reduce or stop.
Methamphetamine use and psychosis: Recognising and addressing the harmful mental health impacts of methamphetamine use (Position Statement 82) (RANZCP, PS #82 (September 2019)). People with methamphetamine dependence are about five times more likely to have psychotic symptoms during periods of use than during abstinence. Methamphetamine psychosis can mimic acute paranoid schizophrenia and is an opportunity for early intervention. Treat methamphetamine use as a public health issue, with harm-minimisation campaigns and diversion from the justice system into treatment. Mental health and AOD services should be integrated, with referral pathways in both directions.
Gambling-related harm: screening and treatment: Prevention and Treatment of Gambling-Related Harm (joint RANZCP–RACP position statement) (RANZCP and RACP, PS #45 (revised 2024)). Screen routinely for harmful gambling at initial assessment, especially in people with mental health or substance use disorders, using tools such as the PGSI. Gambling harm often occurs alongside alcohol, substance use and mood disorders and raises suicide risk. CBT is the most effective treatment, followed by motivational interviewing. Naltrexone may be added, but the evidence is low certainty. Public health measures include banning gambling advertising and limits on electronic gaming machines.
Involuntary psychiatric treatment of prisoners: Involuntary mental health treatment in custody (Position Statement 93) (RANZCP, PS #93 (November 2017)). The College opposes involuntary psychiatric treatment inside prisons. It should happen in designated mental health facilities. Prisoners should receive mental health care equivalent to that available in the community. Prisoners who need involuntary treatment should be transferred to a forensic mental health facility. Bed shortages should not make prison treatment the default. Treatment orders in prison are opposed except as a way to arrange transfer.
People found unfit to stand trial: Principles for the treatment of persons found unfit to stand trial (Position Statement 90) (RANZCP, PS #90 (November 2020)). Indefinite detention of forensic patients breaches their rights. Provide care in the least restrictive appropriate environment. Inpatient care should not be mandatory. Detention should last no longer than needed for assessment, treatment and risk management, and no longer than for comparable non-forensic patients. Forensic patients should be moved out of prison into a health facility.
Responding to a subpoena for psychiatric records: Patient–psychiatrist confidentiality: the issue of subpoenas (Position Statement 89) (RANZCP, PS #89 (October 2016)). Disclosing psychiatric records against a patient's wishes can cause harm, and objecting to a subpoena is often difficult and costly. In some jurisdictions (NSW, WA, Tasmania, ACT), Evidence Acts let courts exclude confidential professional communications. Patients can claim this, but psychiatrists often carry the burden. The College urges courts to close proceedings when psychiatric records are discussed. In Victoria, records of sexual assault victims need leave of the court before they can be subpoenaed.
Medically unstable eating disorders: risk and refeeding: Medical emergencies in eating disorders (MEED): Guidance on recognition and management (CR233) (Royal College of Psychiatrists (UK), CR233 (May 2022)). MEED replaces the MARSIPAN reports (CR189 and CR168) with one guidance document covering all ages. Assess medical risk across several domains (BMI or %median BMI, rate of weight loss, cardiovascular signs, ECG, bloods, muscle strength) using its risk summary tables. Prevent refeeding syndrome by monitoring and correcting electrolytes, and avoid underfeeding, which also causes harm. Includes annexes on type 1 diabetes and eating disorders and summary sheets for assessment.
Eating disorders: psychological treatments: Eating disorders: recognition and treatment (NICE guideline NG69) (NICE (UK), NG69 (2017, updated; last reviewed August 2024)). For anorexia nervosa in children and young people, offer anorexia-focused family therapy first. For adults with anorexia, options include individual eating-disorder-focused CBT (CBT-ED), MANTRA and SSCM. For bulimia and binge eating disorder in adults, start with an eating-disorder-focused guided self-help programme. Do not use medication as the only treatment for anorexia nervosa.
Borderline personality disorder: treatment principles: Clinical Practice Guideline for the Management of Borderline Personality Disorder (NHMRC, 2012). It contains 63 recommendations on diagnosis in adolescents and adults, treatment, and support for carers and families. Structured psychological therapies (for example DBT or MBT) are the main treatment. Medication is not first line for BPD itself. Use it short term in a crisis or for comorbid conditions, and avoid polypharmacy. BPD can be diagnosed in adolescents, and early treatment is encouraged.
Ethics: boundaries and confidentiality: RANZCP Code of Ethics (RANZCP, 5th edition (2018)). There are 11 principles, including respecting dignity and autonomy, not exploiting patients, protecting confidentiality, and getting valid consent. Sexual relationships with current or former patients are always unethical. Breaching confidentiality can be justified in the public interest, such as to protect the safety of the patient or others. Disclose only what is necessary. Confidentiality continues after the therapeutic relationship ends and after the patient's death, with narrow exceptions.
Seclusion and restraint: Minimising and, where possible, eliminating the use of seclusion and restraint (Position Statement 61) (RANZCP, PS #61 (updated March 2026)). Seclusion and restraint are a last resort, used only after other options have been tried or excluded, under protocols, by trained staff. They must never be used as punishment or to make up for too few staff or resources. Reduce their use with trauma-informed and recovery-oriented care, de-escalation spaces, co-design with people with lived experience, and debriefing after incidents. Culturally specific approaches are needed for Aboriginal and Torres Strait Islander, Māori and Pasifika people.
Voluntary assisted dying: the psychiatrist's role: Voluntary assisted dying (Position Statement 67) (RANZCP, PS #67 (updated July 2026)). Capacity assessment for VAD should mainly be done by the primary or coordinating clinicians, not routinely by psychiatrists. Involve a psychiatrist where there is complex mental health comorbidity, after the initial assessments. Capacity is assessed for the decision, not on the basis of a particular diagnosis. Psychiatrists may choose whether and how far to take part and must never be required to participate.
Sexual safety on inpatient units: Sexual safety in mental health services in Australia and New Zealand (Position Statement 114) (RANZCP, PS #114 (September 2023)). Units should provide secure women-only areas (bedrooms, bathrooms, lounges). Mixed areas need extra safeguards such as swipe access and personal alarms. Assess sexual safety like any other risk (both risk from others and risk to others) and make a safety plan. Take every allegation seriously, support everyone involved, and record and report incidents consistently. Services need a sexual safety policy and staff training in trauma-informed, gender-sensitive care.
Dementia: cholinesterase inhibitors and antipsychotics: Clinical Practice Guidelines and Principles of Care for People with Dementia (NHMRC Partnership Centre for Dealing with Cognitive and Related Functional Decline in Older People (NHMRC-approved), 2016). Use non-drug approaches first for BPSD, and look for and treat pain. Cholinesterase inhibitors (donepezil, galantamine, rivastigmine) and memantine can be used in mild to moderate Alzheimer disease. They should not be prescribed for mild cognitive impairment. Avoid antipsychotics for mild to moderate BPSD because they raise the risk of stroke and death. They may be offered for severe distress or risk to others. Review antipsychotics every 4–12 weeks and consider stopping them.
Severe BPSD in residential aged care: short-term antipsychotics: RACGP aged care clinical guide (Silver Book) (RACGP, 5th edition (2019)). Non-drug measures come first. Risperidone (PBS-listed) is used only after they have been tried and failed, and after looking for reversible causes. Reserve antipsychotics for severe agitation or aggression with a risk of harm, or for distressing psychosis. Start at a low dose and review within a week. Plan to wean and stop as soon as possible, preferably before 12 weeks, and review at least 3-monthly. Get and document consent from the patient or their substitute decision-maker, including the risks discussed.
Delirium: screening and the limited role of antipsychotics: Delirium Clinical Care Standard (Australian Commission on Safety and Quality in Health Care, 2021 (revised)). The standard has eight quality statements covering screening, assessment, prevention, management and follow-up. Screen people at risk (for example, older people or those with cognitive impairment) for delirium when they present. Prevention and management rely on non-drug, multicomponent strategies. Antipsychotics are not routinely used to prevent or treat delirium. Use them only for severe distress or risk, at the lowest dose for the shortest time.
Palliative care: the wish to die and prolonged grief: Therapeutic Guidelines: Palliative Care (Therapeutic Guidelines Ltd, 2024 update (published December 2024)). The December 2024 update added a topic on assessing and caring for patients who say they wish to die or want death hastened. Updated advice clarifies the symptoms of prolonged grief disorder and its risk factors, and adds a summary of psychosocial interventions. Assessment and management of distress, anxiety and depression in palliative care are covered in more detail. Deprescribing should start early, using shared decision-making.
Low back pain: avoiding psychotropics and gabapentinoids: Low Back Pain Clinical Care Standard (Australian Commission on Safety and Quality in Health Care, 2022). Assess for serious or specific pathology and screen for psychosocial factors early. Reserve imaging for suspected serious or specific pathology. Encourage staying active and returning to usual activities, including work. Use medicines to enable activity. Avoid anticonvulsants, benzodiazepines and antidepressants for low back pain. Consider opioids only in carefully selected patients, at the lowest dose for the shortest time.
Alcohol use disorder: withdrawal and relapse-prevention drugs: Guidelines for the Treatment of Alcohol Problems (Australian Government-funded expert guideline (Haber et al., University of Sydney), 2021). Use the AUDIT to screen in primary care and hospitals. AUDIT-C is an alternative for community screening. Most withdrawal can be managed as an outpatient with support, using a tapering diazepam regimen with staged daily supply. Acamprosate helps maintain abstinence and naltrexone prevents relapse to heavy drinking (both Level A). Disulfiram is only for supervised, motivated patients. Baclofen and topiramate (off-label) have some evidence but should not be first line.
Safe drinking advice for adults, young people and pregnancy: Australian guidelines to reduce health risks from drinking alcohol (NHMRC, 2020). Healthy adults should drink no more than 10 standard drinks a week and no more than 4 on any one day. People under 18 should not drink alcohol. Not drinking is advised when pregnant or planning a pregnancy, and not drinking is safest while breastfeeding.
Smoking cessation: pharmacotherapy and nicotine vapes: Supporting smoking cessation: A guide for health professionals (RACGP, 2nd edition (2021; updated for October 2024 vaping changes)). Give brief advice to everyone who smokes and offer follow-up and referral to telephone call-back counselling. For nicotine dependence, offer pharmacotherapy with behavioural support. Varenicline is strongly recommended, and combination NRT (patch plus oral form) beats a single form. Bupropion is less effective, and nortriptyline is second line because of its adverse effects. Nicotine vaping products are a conditional option only after first-line therapy has failed, using shared decision-making.
Opioid prescribing for chronic non-cancer pain: Prescribing drugs of dependence in general practice, Part C1: Opioids (RACGP, 2017 (minor updates 2020)). Opioids are generally a short-term option, and long-term use should be uncommon. Prescribe the lowest effective dose for the shortest time. Prescribe from one practice (ideally one GP) and dispense from one pharmacy. Schedule regular attempts to reduce the dose for anyone on long-term opioids. Take care with comorbid substance use and benzodiazepines, which increase the risk of harm. Consider a substance use disorder where relevant.
Hepatitis C: who to treat and who can prescribe: Australasian recommendations for the management of hepatitis C virus infection: a consensus statement (Gastroenterological Society of Australia / ASHM and partners, 2022). Consider all adults with HCV for direct-acting antiviral treatment. Experienced medical practitioners, including GPs, and nurse practitioners can prescribe treatment. Pangenotypic regimens (sofosbuvir/velpatasvir or glecaprevir/pibrentasvir) are standard. Assess for cirrhosis (for example with APRI) before treatment. Confirm cure with an HCV RNA test 12 weeks after treatment, and keep testing people at ongoing risk for reinfection.
Cardiovascular risk in people with severe mental illness: Australian guideline for assessing and managing cardiovascular disease risk (with the Aus CVD Risk Calculator) (Heart Foundation-led national guideline (Australian Chronic Disease Prevention Alliance), 2023). Assess people without known CVD: everyone aged 45–79, people with diabetes aged 35–79, and First Nations people aged 30–79. First Nations people aged 18–29 should have their individual risk factors assessed. Estimated 5-year risk: high is 10% or more, intermediate is 5% to under 10%, and low is under 5%. Risk can be reclassified up or down for ethnicity, coronary artery calcium score, family history, eGFR/uACR and severe mental illness.
Mandatory notification of an impaired colleague you are treating: Guidelines: Mandatory notifications about registered health practitioners (Ahpra and the National Boards, Current guidelines (2020)). There are four types of concern: impairment, intoxication while practising, significant departure from accepted professional standards, and sexual misconduct. Treating practitioners have a higher threshold. For impairment, intoxication or departure from standards, they must notify only if there is a substantial risk of harm to the public. For sexual misconduct the threshold is lower: a reasonable belief that it has occurred, is occurring or is at risk of occurring. In WA, treating practitioners are exempt from the mandatory requirement but may notify voluntarily.
Professional conduct: telehealth, cultural safety and social media: Good medical practice: a code of conduct for doctors in Australia (Medical Board of Australia, October 2020). The code applies to all consultations, including telehealth and online or remote prescribing. It defines cultural safety for Aboriginal and Torres Strait Islander Peoples and extends culturally safe practice to all communities. It sets zero tolerance of discrimination, bullying and sexual harassment. It covers public comment and social media.
Fitness to drive: who decides and the doctor's role: Assessing Fitness to Drive for commercial and private vehicle drivers (Austroads and National Transport Commission, 2022 edition (in effect from 22 June 2022)). The driver licensing authority makes licensing decisions. The health professional assesses the patient and advises it. Private and commercial vehicle standards differ, and commercial standards are stricter. Drivers have a legal duty to report conditions that affect their driving. A health professional can report directly if there is a public safety concern. The standards apply to conditions such as seizures, syncope, diabetes on insulin, sleep disorders, vision, cognitive impairment and psychiatric illness.
ADHD: diagnosis and first-line treatment: Australian Evidence-Based Clinical Practice Guideline for Attention Deficit Hyperactivity Disorder (ADHD) (Australian ADHD Professionals Association (AADPA), 1st edition (October 2022), NHMRC-approved). This is Australia's first NHMRC-approved ADHD guideline. It covers identification, diagnosis and treatment across the lifespan. For school-aged children and adults, stimulant medication (methylphenidate, dexamfetamine or lisdexamfetamine) is a first-line option, alongside non-drug supports. Non-drug interventions such as parent training come first for young children. Monitor medication effects, including growth, appetite, BP and heart rate.
Autism: how assessment and diagnosis should be done: National Guideline for the assessment and diagnosis of autism in Australia (Autism CRC, 2nd edition (2023 update; 2018 edition NHMRC-approved)). Assessment combines a comprehensive needs assessment (including functioning and strengths) with a diagnostic evaluation. The 2023 update renamed the single-clinician pathway the 'Lead Practitioner Diagnostic Evaluation': one clinician leads and draws on input from others. The update has fewer recommendations and adds neurodiversity-affirming practice. Findings should identify support needs, not only give a diagnostic label.
Perinatal depression and anxiety: screening and care: Mental Health Care in the Perinatal Period: Australian Clinical Practice Guideline (Centre of Perinatal Excellence (COPE), 2023). This is the national perinatal mental health guideline. The 2023 edition updates the 2017 guideline. Screen routinely for depression and anxiety with the EPDS in pregnancy and again in the postnatal period, alongside a psychosocial assessment of risk factors. It covers assessment and treatment of depression, anxiety and severe mental illness in pregnancy and the year after birth.
Summaries are written in our own words from each guideline's official page and are for exam study, not clinical use. Guidelines change: check the source before you rely on it.
Practise using them: MEQ and MCQ practice with examiner-style marking →